We have previously shown that SMARCB1-negative MRT tumors are dependent on EZH2 activity [6], and we therefore investigated whether the synovial sarcoma cell lines, with decreased SMARCB1 expression, would likewise display a similar sensitivity to EZH2 inhibition. This evidence concerns the gene SMARCB1 and synovial sarcoma.